文献速递精神分裂症与精神病性障碍儿童青少年精神

技术增强筛查联合临床医生教育对未治疗精神病时长的影响:一项整群随机临床试验

Effect of Technology-Enhanced Screening in Addition to Standard Targeted Clinician Education on the Duration of Untreated Psychosis: A Cluster Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

该整群随机临床试验纳入12至30岁寻求服务者,比较基于人群的电子筛查联合临床医生教育(活性筛查组)与单纯临床医生教育(常规治疗组)对精神病早期发现和未治疗精神病时长(DUP)的影响。结果显示活性筛查组精神病谱系障碍检出率显著更高(5.6% vs 2.6%,P<.001),且DUP小于90天的首发精神病患者比例更高(13例 vs 4例,OR=0.30,95%CI 0.10-0.93,P=.03),但两组平均DUP无差异。结论认为筛查可发现更多未被识别的个体,但未减少DUP。

要点

  • 活性筛查组精神病谱系障碍检出率显著高于常规治疗组(5.6% vs 2.6%,P<.001)。
  • 活性筛查组DUP小于90天的首发精神病患者比例更高(13例 vs 4例,OR=0.30,95%CI 0.10-0.93,P=.03)。
  • 两组平均DUP无显著差异(活性筛查组239.0天[207.4],常规治疗组262.3天[170.2])。

核心结论

  • 基于人群的技术增强筛查在社区环境中检出的精神病谱系障碍个体数是单纯临床判断的两倍以上,但未减少DUP。
  • 显著减少DUP可能需要干预措施来缩短首次精神卫生接触的时间。

研究设计与样本

  • 整群随机临床试验,纳入12至30岁在社区心理健康诊所和学校支持及特殊教育服务机构寻求服务者。
  • 24个站点同意参与,12个站点随机分配至活性筛查组或常规治疗组,最终仅10个社区诊所和4个学校站点完全实施人群筛查并纳入分析。
  • 活性筛查组站点进入2432人,常规治疗组站点进入2455人,共完成303次诊断电话访谈(178例[58.7%]女性;平均[SD]年龄17.09岁[4.57])。

主要发现

  • 活性筛查组报告精神病谱系障碍检出率显著更高(136例[5.6%] vs 65例[2.6%],P<.001)。
  • 活性筛查组转诊的首发精神病且DUP小于90天的个体比例更高(13例 vs 4例;OR=0.30;95%CI 0.10-0.93;P=.03)。
  • 两组平均DUP无差异(活性筛查组239.0天[207.4];常规治疗组262.3天[170.2])。

关键数值与推荐

  • DUP定义为从精神病完全发作到EDAPT诊断电话访谈日期的时段。
  • 主要结局包括DUP和检出的首发精神病或精神病谱系障碍个体数。

临床怎么用

  • 在社区心理健康和学校环境中使用平板电脑完成Prodromal Questionnaire-Brief筛查并结合临床判断转诊,可提高精神病谱系障碍的检出率。
  • 单纯筛查未缩短DUP,临床实践中需同时干预以缩短至首次精神卫生接触的时间。

局限性

  • 24个站点中仅10个社区诊所和4个学校站点完全实施人群筛查并纳入最终分析。
  • 探索性分析完成于2021年5月,主要和次要分析数据于2019年9月和10月进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Reducing the duration of untreated psychosis (DUP) is essential to improving outcomes for people with first-episode psychosis (FEP). Current US approaches are insufficient to reduce DUP to international standards of less than 90 days. OBJECTIVE: To determine whether population-based electronic screening in addition to standard targeted clinician education increases early detection of psychosis and decreases DUP, compared with clinician education alone. DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized clinical trial included individuals aged 12 to 30 years presenting for services between March 2015 and September 2017 at participating sites that included community mental health clinics and school support and special education services. Eligible participants were referred to the Early Diagnosis and Preventative Treatment (EDAPT) Clinic. Data analyses were performed in September and October 2019 for the primary and secondary analyses, with the exploratory subgroup analyses completed in May 2021. INTERVENTIONS: All sites in both groups received targeted education about early psychosis for health care professionals. In the active screening group, clients also completed the Prodromal Questionnaire-Brief using tablets at intake; referrals were based on those scores and clinical judgment. In the group receiving treatment as usual (TAU), referrals were based on clinical judgment alone. MAIN OUTCOMES AND MEASURES: Primary outcomes included DUP, defined as the period from full psychosis onset to the date of the EDAPT diagnostic telephone interview, and the number of individuals identified with FEP or a psychosis spectrum disorder. Exploratory analyses examined differences by site type, completion rates between conditions, and days from service entry to telephone interview. RESULTS: Twenty-four sites agreed to participate, and 12 sites were randomized to either the active screening or TAU group. However, only 10 community clinics and 4 school sites were able to fully implement population screening and were included in the final analysis. The total potentially eligible population size within each study group was similar, with 2432 individuals entering at active screening group sites and 2455 at TAU group sites. A total of 303 diagnostic telephone interviews were completed (178 [58.7%] female individuals; mean [SD] age, 17.09 years [4.57]). Active screening sites reported a significantly higher detection rate of psychosis spectrum disorders (136 cases [5.6%], relative to 65 [2.6%]; P < .001) and referred a higher proportion of individuals with FEP and DUP less than 90 days (13 cases, relative to 4; odds ratio, 0.30; 95% CI, 0.10-0.93; P = .03). There was no difference in mean (SD) DUP between groups (active screening group, 239.0 days [207.4]; TAU group 262.3 days [170.2]). CONCLUSIONS AND RELEVANCE: In this cluster trial, population-based technology-enhanced screening across community settings detected more than twice as many individuals with psychosis spectrum disorders compared with clinical judgment alone but did not reduce DUP. Screening could identify people undetected in US mental health services. Significant DUP reduction may require interventions to reduce time to the first mental health contact. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02841956.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Niendam TA, Loewy R, Savill M, et al. Effect of Technology-Enhanced Screening in Addition to Standard Targeted Clinician Education on the Duration of Untreated Psychosis: A Cluster Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 36598770. doi:10.1001/jamapsychiatry.2022.4436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。